Cite
Utilising integrated bio-behavioural surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey.
MLA
Maher, Lisa, et al. “Utilising Integrated Bio-Behavioural Surveillance (IBBS) to Investigate Declining Hepatitis C Antibody Prevalence among People Who Inject Drugs in the Australian Needle and Syringe Program Survey.” The International Journal on Drug Policy, Sept. 2024, p. 104576. EBSCOhost, https://doi.org/10.1016/j.drugpo.2024.104576.
APA
Maher, L., Wand, H., Heard, S., Starr, M., Zolala, F., Kemp, R., Cunningham, P., Drummer, H., Hellard, M., Kaldor, J., & Dore, G. (2024). Utilising integrated bio-behavioural surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey. The International Journal on Drug Policy, 104576. https://doi.org/10.1016/j.drugpo.2024.104576
Chicago
Maher, Lisa, Handan Wand, Sue Heard, Mitchell Starr, Farzaneh Zolala, Robert Kemp, Phillip Cunningham, et al. 2024. “Utilising Integrated Bio-Behavioural Surveillance (IBBS) to Investigate Declining Hepatitis C Antibody Prevalence among People Who Inject Drugs in the Australian Needle and Syringe Program Survey.” The International Journal on Drug Policy, September, 104576. doi:10.1016/j.drugpo.2024.104576.